Establishing Functional Biomarkers for Spaced Theta-Burst Stimulation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03687892 |
Recruitment Status :
Recruiting
First Posted : September 27, 2018
Last Update Posted : March 25, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy Volunteers | Device: continuous Theta Burst Stimulation Device: intermittent Theta Burst Stimulation | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 10 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Basic Science |
Official Title: | Establishing Functional Biomarkers for Spaced Theta-Burst Stimulation |
Actual Study Start Date : | April 1, 2019 |
Estimated Primary Completion Date : | April 1, 2023 |
Estimated Study Completion Date : | April 1, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: continuous Theta Burst Stimulation
The investigators will perform two applications of 40s of continuous Theta Burst Stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
|
Device: continuous Theta Burst Stimulation
Continuous Theta Burst Simulation will be applied in a continuous manner resulting in cortical excitability.
Other Name: cTBS |
Experimental: intermittent Theta Burst Stimulation
The investigators will perform two applications of 40s of intermittent Theta Burst Stimulation (iTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
|
Device: intermittent Theta Burst Stimulation
Intermittent Theta Burst Stimulation will be applied in an intermittent manner resulting in cortical inhibition.
Other Name: iTBS |
- Changes in Motor Evoked Potential [ Time Frame: Prior to and and immediately after TBS sessions on each day (separated by 3+ days) ]To determine the duration of effect of an application of a spaced TBS stimulation session (both inhibitory, cTBS and excitatory, iTBS) as measured by duration of change in motor evoked potential.
- Change from baseline resting-state functional connectivity between the M1 hotspot and other motor areas immediately post-TBS [ Time Frame: Prior to and and immediately after TBS sessions on each day (separated by 3+ days) ]To determine the resting state functional connectivity changes that result from an application of spaced TBS stimulations (both inhibitory, cTBS and excitatory, iTBS).
- Change from baseline motor cortex activity as assessed by the BOLD signal immediately post-TBS [ Time Frame: Prior to and and immediately after TBS sessions on each day (separated by 3+ days) ]To determine the TMS-BOLD (over M1) changes that result from an application of spaced TBS stimulations (both inhibitory, cTBS and excitatory, iTBS).
- Changes in arterial perfusion [ Time Frame: Prior to and and immediately after TBS sessions on each day (separated by 3+ days) ]To determine the arterial perfusion changes that result from an application of spaced TBS stimulations (both inhibitory, cTBS and excitatory, iTBS) as measured by ASL.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 18 or older
- Right-handed
- Agree to having fMRI scan
- Willingness to suspend use of analgesic drugs or cough suppressants for 24 hours prior to the scans
- Proficiency in English sufficient to complete questionnaires/follow instructions during fMRI assessments
- US Citizen or resident able to receive payment legally
Exclusion Criteria:
- A medical condition that would contraindicate the use of rTMS
- Any condition that would contraindicate MRI (like ferromagnetic metal in the body)
- Pregnancy or breast feeding
- Any significant neurologic disease, including dementia, multi-infarct dementia, Parkinson's or Huntington's disease, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of significant head trauma
- Current antidepressant use (must be washed out for two weeks prior to starting protocol)
- Inability to stop taking medication contraindicated with treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03687892
Contact: Romina Nejad, M.Sc | (650)736-2233 | rnejad@stanford.edu |
United States, California | |
Stanford University | Recruiting |
Palo Alto, California, United States, 94305 | |
Contact: Romina Nejad, M.Sc 650-736-2233 rnejad@stanford.edu |
Principal Investigator: | Nolan Williams, M.D. | Stanford University |
Responsible Party: | Nolan R, Instructor of Psychiatry and Behavioral Sciences, Stanford University |
ClinicalTrials.gov Identifier: | NCT03687892 |
Other Study ID Numbers: |
39234 |
First Posted: | September 27, 2018 Key Record Dates |
Last Update Posted: | March 25, 2021 |
Last Verified: | March 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | Undecided. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
repetitive Transcranial Magnetic Stimulation functional MRI Theta Burst Stimulation |